Fosphenytoin: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "6 mg" to "6mg") |
(Text replacement - " phenytoin" to " phenytoin") |
||
| Line 11: | Line 11: | ||
**Initial Maintenance: 4-6mg/kg/day IV/IM | **Initial Maintenance: 4-6mg/kg/day IV/IM | ||
*Short-Term Substitution for PO Phenytoin | *Short-Term Substitution for PO Phenytoin | ||
**Can be substituted for PO phenytoin therapy at the same total daily dose | **Can be substituted for PO [[phenytoin]] therapy at the same total daily dose | ||
*Administration | *Administration | ||
**Maximum IV rate of 150mg PE/min | **Maximum IV rate of 150mg PE/min | ||
*Monitor: phenytoin level 2 hr after IV, 4 hr after IM | *Monitor: [[phenytoin]] level 2 hr after IV, 4 hr after IM | ||
*All dosing in mg "phenytoin equivalents" (PE); 75mg fosphenytoin equivalent to 50mg phenytoin | *All dosing in mg "phenytoin equivalents" (PE); 75mg fosphenytoin equivalent to 50mg [[phenytoin]] | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
| Line 36: | Line 36: | ||
*'''Black Box Warnings''' | *'''Black Box Warnings''' | ||
**Cardiovascular risk associated with rapid infusion rates | **Cardiovascular risk associated with rapid infusion rates | ||
**Risk of hypotension and arrhythmias with infusion rates that exceed 150mg/minute of phenytoin sodium equivalents (PE) | **Risk of hypotension and arrhythmias with infusion rates that exceed 150mg/minute of [[phenytoin]] sodium equivalents (PE) | ||
**Careful cardiac monitoring is needed during and after administering IV administration | **Careful cardiac monitoring is needed during and after administering IV administration | ||
**These events have also been reported at or below 150mg/minute | **These events have also been reported at or below 150mg/minute | ||
| Line 80: | Line 80: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: 15 min (phenytoin) | *Half-life: 15 min (phenytoin) | ||
*Metabolism: CYP450; prodrug metabolized to phenytoin | *Metabolism: CYP450; prodrug metabolized to [[phenytoin]] | ||
*Excretion: urine | *Excretion: urine | ||
*Mechanism of Action: modulates neuronal voltage-dependent Na and Ca channels | *Mechanism of Action: modulates neuronal voltage-dependent Na and Ca channels | ||
Revision as of 08:13, 3 August 2016
General
- Type: Anticonvulsants
- Dosage Forms: IM/IV
- Common Trade Names: Cerebyx
Adult Dosing
- Generalized Convulsive Status Epilepticus
- 15-20mg/kg IV, infuse at 100-150mg/min
- Nonemergent Seizure
- Load: 10-20mg/kg IV/IM
- Initial Maintenance: 4-6mg/kg/day IV/IM
- Short-Term Substitution for PO Phenytoin
- Can be substituted for PO phenytoin therapy at the same total daily dose
- Administration
- Maximum IV rate of 150mg PE/min
- Monitor: phenytoin level 2 hr after IV, 4 hr after IM
- All dosing in mg "phenytoin equivalents" (PE); 75mg fosphenytoin equivalent to 50mg phenytoin
Pediatric Dosing
- Safety and efficacy not established
Special Populations
- Pregnancy Rating: D
- Lactation: excretion in milk unknown, not recommended
- Renal Dosing: not defined, caution advised
- Hepatic Dosing: not defined, caution advised
Contraindications
- Allergy to class/drug
- Sinus bradycardia, sinoatrial block, 2nd or 3rd degree AV block, Adams-Stokes syndrome
- Not indicated for absence seizures or seizures secondary to hypoglycemia or other metabolic disorder
- Coadministration with delavirdine; potential for loss of virologic response and possible resistance to delavirdine or to the pharmacologic class of NNRTIs
Adverse Reactions
Serious
- Black Box Warnings
- Cardiovascular risk associated with rapid infusion rates
- Risk of hypotension and arrhythmias with infusion rates that exceed 150mg/minute of phenytoin sodium equivalents (PE)
- Careful cardiac monitoring is needed during and after administering IV administration
- These events have also been reported at or below 150mg/minute
- Reduce infusion rate or discontinuation may be needed
- Cardiovascular collapse
- Toxic delirium
- Bradycardia
- Arrhythmias
- Exfoliative dermatitis
- Stevens-Johnson
- Toxic epidermal necrolysis
- Drug rash with eosinophilia and systemic sx
- Hepatotoxicity
- Thrombocytopenia
- Leukopenia
- Agranulocytosis
- Pancytopenia
- Anemia
- Purple glove syndrome (IV use)
Common
- Nystagmus
- Dizziness
- Pruritis
- Paresthesia
- Headache
- Somnolence
- Ataxia
- Nausea
- Tinnitus
- Rash
- Tremor
- Hypotension
- Xerostomia
- Confusion
- Blurred vision
- Taste changes
- Fever
- Injection site reaction
- Constipation
- Hypokalemia
Pharmacology
- Half-life: 15 min (phenytoin)
- Metabolism: CYP450; prodrug metabolized to phenytoin
- Excretion: urine
- Mechanism of Action: modulates neuronal voltage-dependent Na and Ca channels
See Also
References
epocrates, medscape